Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 20:12:20406207211013985.
doi: 10.1177/20406207211013985. eCollection 2021.

Treosulfan-based conditioning for inborn errors of immunity

Mary A Slatter  1 , Andrew R Gennery  2
Affiliations
Review

Treosulfan-based conditioning for inborn errors of immunity

Mary A Slatter et al. Ther Adv Hematol. .

Abstract

Inborn errors of immunity (IEI) are inherited disorders that lead to defects in the development and/or function of the immune system. The number of disorders that can be treated by haematopoietic stem-cell transplantation (HSCT) has increased rapidly with the advent of next-generation sequencing. The methods used to transplant children with IEI have improved dramatically over the last 20 years. The introduction of reduced-toxicity conditioning is an important factor in the improved outcome of HSCT. Treosulfan has myeloablative and immunosuppressive properties, enabling engraftment with less toxicity than traditionally used doses of busulfan. It is firmly incorporated into the conditioning guidelines of the Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. Unlike busulfan, pharmacokinetically guided dosing of treosulfan is not part of routine practice, but data are emerging which indicate that further improvements in outcome may be possible, particularly in infants who have a decreased clearance of treosulfan. It is likely that individualized dosing, not just of treosulfan, but of all agents used in conditioning regimens, will be developed and implemented in the future. This will lead to a reduction in unwanted variability in drug exposure, leading to more predictable and adjustable exposure, and improved outcome of HSCT, with fewer late adverse effects and improved quality of life. Such conditioning regimens can be used as the basis to study the need for additional agents in certain disorders which are difficult to engraft or require high levels of donor chimerism, the dosing of individual cellular components within grafts, and effects of adjuvant cellular or immunotherapy post-transplant. This review documents the establishment of treosulfan worldwide, as a safe and effective agent for conditioning children with IEI prior to HSCT.

Keywords: haematopoietic stem cell transplantation; inborn errors of immunity; treosulfan.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

References

    1. Tangye SG, Al-Herz W, Bousfiha A, et al.. Human inborn errors of immunity: 2019 update on the classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol 2020; 40: 24–64. - PMC - PubMed
    1. Fischer A, Notarangelo LD, Neven B, et al.. Severe combined immunodeficiencies and related disorders. Nat Rev Dis Primers 2015; 1: 15061. - PubMed
    1. Gatti RA, Meuwissen HJ, Allen HD, et al.. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968; 2: 1366–1369. - PubMed
    1. De Koning J, Van Bekkum DW, Dicke KA, et al.. Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet 1969; 293: 1223–1227. - PubMed
    1. Bach FH, Albertini RJ, Joo P, et al.. Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet 1968; 2: 1364–1366. - PubMed

LinkOut - more resources